In a remarkable leap for reproductive medicine, German biotech startup Ovo Labs has unveiled groundbreaking therapies designed to “rejuvenate” human eggs, potentially making it far easier for millions to conceive through IVF. Founded in January 2025, Ovo Labs is the brainchild of renowned fertility expert Professor Melina Schuh, fertility scientist Dr. Agata Zielinska, and biotech innovator Dr. Oleksandr Yagensky. Their mission: to address one of IVF’s biggest challenges—egg quality. For decades, IVF has offered hope to individuals and couples struggling with infertility. However, it often demands a heavy emotional, financial, and psychological toll. Many women endure multiple IVF cycles without success, and some never achieve their dream of parenthood. Ovo Labs aims to change that story. “By helping to increase the number of viable eggs, we aim to extend the reproductive window, empowering more couples to have children at a time that feels right to them,” Schuh said in a statement. Backed by 20 years of research, Ovo Labs’ approach focuses on reducing genetic errors within eggs. Their three therapeutic treatments could significantly improve the number of viable eggs available during IVF, potentially increasing the odds of a successful pregnancy with just one cycle. The foundation for Ovo Labs’ technology is strong. The startup has already demonstrated success in preclinical models, including aging mice, where their treatments enhanced egg quality. They have also successfully treated isolated human eggs in laboratory conditions. However, the journey toward clinical use is just beginning. Human trials have not yet been approved, and medical treatments typically face long regulatory paths. Still, Ovo Labs is optimistic about the future. To fuel their development and navigate the complex approval process, the startup just announced its first funding round, securing €4.6 million from leading investors including Creator Fund, Local Globe, Blue Wire Capital, Ahren Innovation Capital, and angel investor Antonio Pellicer. “It is inspiring to see European scientists of this calibre launch a company solving such a fundamental question facing humanity,” said Jamie Macfarlane, founder of Creator Fund. Egg quality plays a pivotal role in fertility outcomes. By the age of 40, over 70% of a woman’s eggs carry genetic abnormalities, according to the London Egg Bank. These abnormalities significantly reduce the chances of conception and increase the risk of miscarriage. Ovo Labs’ therapies aim to intervene at this crucial biological bottleneck, offering new hope to older women or those who have delayed childbirth for personal or professional reasons. Schuh and Zielinska’s expertise is rooted in years of collaboration at the Bourn Hall Clinic, the world’s first IVF center, famously featured in Netflix’s Joy. Their earlier research illuminated why egg quality declines with age and how it might be restored. The promise is real, but challenges remain. Gaining regulatory approval is a notoriously slow process, often taking years even for promising treatments. Additionally, rigorous human trials are needed to prove both safety and effectiveness before the therapy can become part of mainstream IVF protocols. Still, the enthusiasm surrounding Ovo Labs is hard to ignore. Their work represents not just a scientific breakthrough but a profound social shift: enabling more people to build families later in life, without the heartbreak so often associated with failed IVF attempts. As the fertility industry evolves, innovations like these could fundamentally reshape reproductive possibilities for millions. And Ovo Labs is just getting started.A Science-Backed Promise
The Urgency Behind the Innovation
What’s Next for Ovo Labs?
Fertility Breakthrough: New Tech Could Boost IVF Success Dramatically
In a remarkable leap for reproductive medicine, German biotech startup Ovo Labs has unveiled groundbreaking therapies designed to “rejuvenate” human eggs, potentially making it far easier for millions to conceive through IVF.